Driven by technological advances and investigator demand, this Core has expanded from the original goal of providing DNA microarray service to include proteomics and metabolomics, thus providing an integrated approach to assessing cell and tissue responses to toxic exposure. First, the microarray service will provide transcriptomic profiling for investigation of toxic endpoints. To this end, it will prepare glass slides with high density arrays (e.g., 20,000 elements) of long oligonucleotides representing transcribed genes from human, mouse or rat. It will also prepare slides on demand containing smaller arrays or (subject to availability) DNA representing transcripts or genes from other species. The Core will process the slides or train lab personnel in this function as requested and, in concert with Core B, will assist in data processing. Second, the Core will provide proteomics services including profiling (with protein separation and mass spectrometric identification) and analysis of posttranslational modifications (phosphorylation, sulfhydryl oxidation). The Core will also provide services for metabolomic investigations such as profiling of metabolic subdomains and metabolic fingerprinting (including phase II metabolism). Validated analyses of metabolic subdomains include the quantitative assessment of both regulatory oxylipids (for the study of tissue responses to inflammatory injury and general repair mechanisms) and structural/energetic lipids (for the study of toxicant effects on cell/organism energy utilization). Metabolic fingerprinting provides tools for an expansive exploration of toxicant effects on the small molecule milieu of tissues, cells, and biofluids. Integrating themes are to find characteristic responses to given agents, identifying biomarkers of early response, and finding no effect levels for the most sensitive biomarkers of effect. The emphasis will be on increasing Project productivity and efficiency of resource utilization. Thus highly trained Core personnel will help in planning experiments, will concentrate their efforts on technically demanding functions, and will train Project personnel in conducting their own experiments where feasible. The Core will provide data storage and assistance in data analysis.

Agency
National Institute of Health (NIH)
Institute
National Institute of Environmental Health Sciences (NIEHS)
Type
Hazardous Substances Basic Research Grants Program (NIEHS) (P42)
Project #
5P42ES004699-21
Application #
7391806
Study Section
Special Emphasis Panel (ZES1)
Project Start
Project End
Budget Start
2007-04-01
Budget End
2008-03-31
Support Year
21
Fiscal Year
2007
Total Cost
$334,164
Indirect Cost
Name
University of California Davis
Department
Type
DUNS #
047120084
City
Davis
State
CA
Country
United States
Zip Code
95618
Taha, Ameer Y; Hennebelle, Marie; Yang, Jun et al. (2018) Regulation of rat plasma and cerebral cortex oxylipin concentrations with increasing levels of dietary linoleic acid. Prostaglandins Leukot Essent Fatty Acids 138:71-80
Hill 3rd, Thomas; Rice, Robert H (2018) DUOX expression in human keratinocytes and bronchial epithelial cells: Influence of vanadate. Toxicol In Vitro 46:257-264
Kodani, Sean D; Wan, Debin; Wagner, Karen M et al. (2018) Design and Potency of Dual Soluble Epoxide Hydrolase/Fatty Acid Amide Hydrolase Inhibitors. ACS Omega 3:14076-14086
Ren, Qian; Ma, Min; Yang, Jun et al. (2018) Soluble epoxide hydrolase plays a key role in the pathogenesis of Parkinson's disease. Proc Natl Acad Sci U S A 115:E5815-E5823
Pecic, Stevan; Zeki, Amir A; Xu, Xiaoming et al. (2018) Novel piperidine-derived amide sEH inhibitors as mediators of lipid metabolism with improved stability. Prostaglandins Other Lipid Mediat 136:90-95
Yamanashi, Haruto; Boeglin, William E; Morisseau, Christophe et al. (2018) Catalytic activities of mammalian epoxide hydrolases with cis and trans fatty acid epoxides relevant to skin barrier function. J Lipid Res 59:684-695
Wang, Fuli; Zhang, Hongyong; Ma, Ai-Hong et al. (2018) COX-2/sEH Dual Inhibitor PTUPB Potentiates the Antitumor Efficacy of Cisplatin. Mol Cancer Ther 17:474-483
Napimoga, M H; Rocha, E P; Trindade-da-Silva, C A et al. (2018) Soluble epoxide hydrolase inhibitor promotes immunomodulation to inhibit bone resorption. J Periodontal Res 53:743-749
Blöcher, René; Wagner, Karen M; Gopireddy, Raghavender R et al. (2018) Orally Available Soluble Epoxide Hydrolase/Phosphodiesterase 4 Dual Inhibitor Treats Inflammatory Pain. J Med Chem 61:3541-3550
Hao, Lei; Kearns, Jamie; Scott, Sheyenne et al. (2018) Indomethacin Enhances Brown Fat Activity. J Pharmacol Exp Ther 365:467-475

Showing the most recent 10 out of 1149 publications